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CENTRAL PICTURE LEGEND 56 
Right ventricular function deteriorates following lung resection and remains depressed two 57 
months postoperatively. 58 
 59 
CENTRAL MESSAGE (200 characters - 186) 60 
Right ventricular ejection fraction is reduced immediately following lung resection. These 61 
changes are still present at two months, suggesting peri-operative changes in RV function 62 
may have an influence long in to the recovery period. 63 
 64 
PERSPECTIVE STATEMENT (405 characters - 371) 65 
There is growing interest in the role of RV dysfunction in cardiorespiratory morbidity 66 
following lung resection. Using cardiovascular magnetic resonance, this study demonstrates 67 
postoperative RV dysfunction with increased pulsatile afterload, predominantly arising from 68 
the operative pulmonary artery. The deterioration in RV function may provide a therapeutic 69 
target for future interventions seeking to ameliorate the burden of morbidity in this 70 
population.   71 
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ABSTRACT 72 
Objectives 73 
Lung cancer is a leading cause of cancer death and in suitable cases the best chance of cure is 74 
offered by surgery. Lung resection however is associated with significant post-operative 75 
cardiorespiratory morbidity, with dyspnea and reduced functional capacity as dominant 76 
features. These changes are poorly associated with deterioration in pulmonary function and a 77 
potential role of right ventricular (RV) dysfunction has been hypothesized. Cardiovascular 78 
magnetic resonance (CMR) is a reference method for non-invasive assessment of RV 79 
function and has not previously been applied to this population.  80 
 81 
Methods 82 
We used CMR to assess the RV response to lung resection. CMR with volume and flow 83 
analysis was performed on 27 patients pre-operatively, on post-operative day (POD) 2 and at 84 
2-months. Left and right ventricular ejection fraction (L- & RVEF), the ratio of Stroke 85 
Volume to End Systolic Volume (SV/ESV), pulmonary artery acceleration time (PAAT) and 86 
distensibility (of main and branch pulmonary arteries) were studied. 87 
 88 
Results 89 
Mean (Standard Deviation) RVEF deteriorated from 50.5% (6.9) pre-operatively, to 45.6% 90 
(4.5) on POD2 and remained depressed at 44.9% (7.7) by 2-months (p=0.003). SV/ESV 91 
deteriorated from 1.0 (0.9, 1.2) pre-operatively to 0.8 (0.7, 1.0) on POD2 (p=0.011). On 92 
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POD2 there was a decrease in PAAT and operative pulmonary artery distensibility (p<0.030 93 
for both). There were no changes in LVEF  during the study period (p=0.621). 94 
Conclusions 95 
These findings suggest RV dysfunction occurs following lung resection and persists 2-96 
months after surgery. The deterioration in SV/ESV suggests a mismatch between afterload 97 
and contractility. There is an increase in indices of pulsatile afterload resulting from the 98 
operative pulmonary artery. 99 
 100 
CLINICAL TRIALS REGISTRATION 101 
ClinicalTrials.gov (NCT01892800)  102 
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INTRODUCTION 103 
Lung resection is associated with high cardio-respiratory complication rates1, 2 and significant 104 
long-term morbidity, with many patients experiencing disabling dyspnea and decreased 105 
functional capacity.3, 4 These changes are poorly associated with lung function,5, 6 and may be 106 
influenced by cardiac limitation.7, 8 Given their close relationship, complex interaction and 107 
potential for disruption during lung resection, previous work has focussed on the right 108 
ventricular/pulmonary vascular unit. 109 
Several studies have described a 15-25% relative reduction in right ventricular ejection 110 
fraction (RVEF) following lung resection;9-14 patients experiencing a greater decline in RV 111 
function are more likely to suffer post-operative complications.12-14 Lewis et al demonstrated 112 
that impaired RV function intra-operatively identified patients in whom late cardio-113 
respiratory symptoms would develop,11 suggesting peri-operative RV dysfunction has an 114 
impact long into the post-operative period. 115 
Assessing RV function is challenging because of the RV’s complex geometry, retrosternal 116 
position and marked load dependence.15-17 Previous studies in this population have been 117 
hampered by the limitations of the techniques used (mainly volumetric pulmonary artery 118 
catheters (vPAC's);9, 11, 18 in many cases leading to conflicting results. The validity of vPAC's 119 
has been challenged, with the observation that their accuracy has never been convincingly 120 
demonstrated.19, 20  121 
The primary mechanism of RV dysfunction following lung resection is hypothesized to result 122 
from increased afterload.11, 12, 18 Though this seems intuitive, studies measuring pulmonary 123 
vascular resistance (PVR), as an index of RV afterload, have been unable to demonstrate 124 
sustained changes post-operatively. PVR rises intra-operatively, during one-lung ventilation 125 
and on pulmonary artery clamping, but returns to baseline by 24 hours.10, 18, 21 Whilst PVR is 126 
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commonly used in clinical practice, this measure of opposition to mean flow (static afterload) 127 
ignores the pulsatile component of afterload.17 Up to half of the hydraulic power in the main 128 
pulmonary artery is contained in the pulsatile components of flow; comprising resistance, 129 
capacitance, inertia and pulse wave reflection; as such true RV afterload – the RV input 130 
impedance, is a composite of both static and pulsatile components.16, 17  131 
Given the methodological concerns regarding the techniques used to assess RV function in 132 
previous studies and ongoing uncertainty about underlying mechanism, further work was 133 
required to understand the RV response to lung resection. Cardiovascular Magnetic 134 
Resonance (CMR) is the non-invasive gold standard method for assessing RV structure and 135 
function.15, 16 In addition to accurate quantification of volumes, CMR allows pulmonary 136 
artery flow quantification,15, 22 meaning pulsatile components of afterload can be explored.23  137 
Although RVEF is a commonly used index of function, it is highly load dependent and 138 
doesn't fully reflect RV contractility.16 Changes in RVEF can therefore result from alterations 139 
in the loading conditions, contractility or a combination. A more comprehensive assessment 140 
of RV and pulmonary vascular function can be provided by considering the matching 141 
between contractility and afterload. Maximal ventricular elastance (Emax) is a load-142 
independent parameter used to characterize RV contractility. Arterial elastance (Ea) is an 143 
index of afterload faced by the ventricle. The ratio of these two elastances (Emax/Ea) reflects 144 
right ventricular-pulmonary artery coupling (coupling) and reflects matching between the 145 
ventricle and pulmonary circulation. An estimate of coupling can be obtained non-invasively 146 
with CMR, using a ratio of volume measurements (SV/ESV). 24 147 
The aim of this CMR imaging study was to provide a comprehensive understanding of 148 
changes in the RV/pulmonary vascular unit following lung resection.24 Plasma biomarkers of 149 
myocardial dysfunction were measured contemporaneously.  150 
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METHODS 151 
Subjects 152 
Ethics approval was provided by the West of Scotland Research Ethics Committee 153 
(134/WS/0055) and all participants provided written informed consent. Patients attending for 154 
elective lung resection by thoracotomy and lobectomy were screened. Subjects who were 155 
pregnant, participating in any investigational research which could undermine the scientific 156 
basis of the study, had contraindications to CMR imaging or were undergoing; 157 
wedge/segmental/sub-lobar lung resection, pneumonectomy, isolated middle lobectomy or 158 
thoracoscopic/minimal access lung resection, were excluded. Surgical technique was 159 
standardized to a single surgeon performing a postero-lateral muscle sparing thoracotomy 160 
with anatomically appropriate lymph node clearance. Anesthetic technique was standardized 161 
and included volatile agents for anesthetic maintenance, intra-operative lung protective 162 
ventilatory strategies and thoracic epidural blockade. 163 
Measurements 164 
Cardiovascular Magnetic Resonance Imaging 165 
CMR was performed within 24 hours pre-operatively, on post-operative day (POD) 2 and at 166 
2-months (1.5 Tesla, Siemens Avanto, Siemens, Erlangen, Germany). ECG-gated fast 167 
imaging steady state free precession cines (TrueFISP, Siemens) were utilized throughout. 168 
Methodological details of importance include standardized imaging parameters of repetition 169 
time, echo time, flip angle, voxel size, field of view = 4.3ms, 1.2ms, 60o, 1.4 x 1.4 x 6mm, 170 
340mm respectively; 6mm imaging slices were used with a 4mm interslice gap. Short axis 171 
imaging was performed during breath holds and initiated at the atrioventricular valve plane 172 
and propagated sequentially to the cardiac apex providing complete coverage of both 173 
ventricles. Analysis of randomized and anonymized images was performed by two 174 
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independent reporters using proprietary software (Argus, Siemens, Erlangen, Germany). RV 175 
and left ventricular (LV) volumes were determined by manual planimetry of short-axis 176 
images according to standard methods.25 The ratio of RV stroke volume to end-systolic 177 
volume (RVSV/RVESV) was derived as an index of right ventriculo-arterial coupling.24 178 
Flow imaging was performed with velocity encoded gradient sequencing of the main 179 
pulmonary artery (PA) and of both left and right pulmonary arteries. Mapping was set for the 180 
main PA perpendicular to the vessel and above the valve level with velocity encoding at 181 
150cm/s. Mapping for the branch PA's was perpendicular to the vessel, proximal to 1st 182 
dividing vessel with velocity encoding at 150cm/s. Main and branch pulmonary artery 183 
contours were delineated by manual planimetry. Cubic splines with interpolation to 1ms 184 
temporal resolution were then fitted to flow and area versus time curves allowing calculation 185 
of pulmonary artery acceleration time (PAAT) and distensibility for the main and branch 186 
pulmonary arteries.26  PAAT is the time to peak flow (ms) from the onset of the cardiac 187 
cycle, distensibility (%) was calculated as 100*(max-min PA area)/min PA area.  188 
Biomarkers of myocardial function 189 
Blood samples were collected pre-operatively, immediately post-operatively, on the morning 190 
of POD's 1 & 2 and at 2-months. B-type natriuretic peptide (BNP) was analysed immediately 191 
using the Alere Triage system (Alere, Stockport, UK). High sensitivity Troponin T (hsTnT) 192 
was analysed immediately using the Roche-cobas 6000e analyser (Roche, Basel, 193 
Switzerland). 194 
Statistical Methods 195 
Power analysis was carried out in consultation with the Robertson centre for biostatistics at 196 
the University of Glasgow. Primary outcome was change in RVEF on POD2. Although the 197 
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validity of previous work has been questioned, these studies suggested an absolute fall in 198 
RVEF of 6-9% by POD29, 10 and our study was powered to detect a change of at least this 199 
magnitude. They also suggest that mean RVEF is 45% and that the largest standard deviation 200 
is assumed to be 7%. Power analysis was based on a 2-sided, paired t-test and indicated that 201 
19 patients would have 80% power to detect an absolute reduction in RVEF of 6%, with a 202 
significance level of 0.05. Allowing a margin of 30% for study withdrawal, 28 patients were 203 
recruited. 204 
Data are presented as mean (Standard Deviation, SD) or median (Q1, Q3) as appropriate. 205 
Changes over time were assessed using one-way repeated measures ANOVA or Friedman's 206 
test with post-hoc pairwise comparisons using paired t-test or Wilcoxon signed rank test. 207 
Comparisons between independent groups were performed using the independent t test or 208 
Mann-Whitney U test. Association between continuous variables was assessed using 209 
Pearson's or Spearman's correlation coefficients. Bonferroni corrected p values are presented 210 
throughout. 211 
Statistical analyses were performed using SPSS for Windows, version 22 (IBM Corp, 212 
Armonk, NY, USA). A p value <0.05 was considered significant.   213 
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RESULTS 214 
Twenty-eight patients were recruited. One patient was excluded due to the unexpected 215 
discovery of an embedded piece of ferromagnetic material in their chest wall during pre-216 
operative scanning, meaning no usable images could be obtained. There were no clinical 217 
sequelae but as this patient was unable to take any part in the main study, the patient was 218 
removed from all further analyses. Patient demographics are displayed in Table 1. Twenty-six 219 
patients underwent lobectomy or bilobectomy (incorporating the right middle lobe); one 220 
patient required unplanned intra-operative conversion to a pneumonectomy and is included in 221 
all analyses. Sensitivity analysis revealed this patient was not an outlier in any analysis (not 222 
shown). 223 
CMR was well tolerated, with all patients completing the scan protocol pre-operatively. Due 224 
to an administration error, one participant did not have short axis images obtained meaning it 225 
was not possible to calculate ventricular volumes in this patient. Twenty-two (81.5%) patients 226 
completed the protocol on POD2 and 24 (88.9%) at 2-months. Time to final follow-up was 227 
55.9 (13.1) days. Of the 5 patients unable to be scanned on POD2; three declined, one was 228 
unwell with persistent air-leak requiring additional inter-costal catheter drainage with CMR 229 
transfer deemed unsafe, and one patient had an epidural catheter in-situ that was not CMR 230 
compatible. Of the patients unable to complete the protocol at 2-months; one declined, one 231 
was an inpatient at another hospital and the third had a contraindication to CMR as a result of 232 
recent cataract surgery. The baseline characteristics of those completing and non completing 233 
follow-up are described in supplementary table 1. 234 
CMR ventricular volumetric and flow velocity mapping 235 
Coefficient of variation (SD/mean) for RVEF was 12.9% pre-operatively, 16.8% on POD2 236 
and 15.9% at 2-months. Mean (SD) RVEF fell from 50.5% (6.9) pre-operatively, to 45.6% 237 
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(4.5) on POD2 and remained reduced at 44.9% (7.7) at 2-months (p=0.003, Table 2 and 238 
Figure 1A). There were no changes in left ventricular (LV) ejection fraction over the study 239 
period (p=0.621, Figure 1B). There was a deterioration in the ratio of RV stroke volume to 240 
RV end systolic volume (RVSV/RVESV) on POD2 which persisted at 2-months (p=0.011, 241 
Table 2 and Figure 1C). 242 
RVESV increased on POD2, returning to baseline levels at 2-months. LV end diastolic 243 
volume, end systolic volume and stroke volume were unchanged on POD2. All other left and 244 
right ventricular volumes were reduced at 2-months (Table 2).  245 
Main pulmonary artery flow increased from 6.6L/min (1.7) to 8.00L/min (1.6) on POD2, 246 
returning to baseline (6.52L/min (1.7)) by 2-months (p=0.004, Table 3 and Figure 2A). This 247 
increase in CO resulted from increased heart rate (Table 2). Pre-operatively there was an even 248 
distribution of CO between the left and right PA's (48.1% and 51.9%, p=0.055). This 249 
distribution was altered post-operatively with 66.3% and 60.9% of the CO travelling through 250 
the non-operative vessel on POD2 and at 2-months respectively (p<0.001, Table 3 and Figure 251 
2B). 252 
POD2 PAAT was reduced in all vessels with PAAT shorter in the operative versus non-253 
operative vessel. At 2-months, PAAT remained shorter than pre-operative values in the main 254 
PA and operative vessel. At 2-months operative PAAT was again shorter than non-operative 255 
PAAT (Table 3 and Figures 3A & B).  256 
Main PA distensibility was unchanged throughout the study. Non-operative PA distensibility 257 
increased in comparison to POD2 at 2-months, and was higher than the operative vessel at 258 
this time-point (Table 3 and Figure 3C).  There were no consistent associations between 259 
PAAT, distensibility and RVEF at any time (Supplementary tables 2 and 3).  260 
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There is a moderate positive association between the transfer factor for carbon monoxide 261 
(TLCO) and the change in RVEF from pre-operative to POD2 (ΔRVEFPOD2-pre, Pearson's 262 
r=0.517, p=0.014, supplementary figure 5).. There was no association between any of the 263 
operative variables described in Table 1 and any the CMR variables (RVEF, PAAT and 264 
distensibility). There was a strong negative association between RVEF on POD2 and the 265 
duration of critical care unit stay (Spearman's r=-0.653, p=0.001, supplementary figure 6). 266 
There was no association between RVEF at any timepoint and duration of hospital stay. 267 
 268 
Biomarkers of myocardial function 269 
Coefficients of variation for BNP and hsTnT were 5.9% and <10% respectively. BNP 270 
increased over time, peaking on POD2 and returning to baseline by 2-months (Table 4 and 271 
Figure 4A). HsTnT showed a small but significant post-operative rise (Table 4 and Figure 272 
4B). There was moderate association between ΔRVEFPOD2-pre and BNP on POD2 (Pearson's 273 
r=-0.490, p=0.021, Figure 4C). There was no association between troponin and RVEF on 274 
POD2 (Figure 4D). Associations at other time points are detailed in supplementary table 4.  275 
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DISCUSSION 276 
The main finding of this study (the first using CMR to describe changes in RV function 277 
following lung resection) is that RV function deteriorated by POD2 and remained depressed 278 
at 2-months.  This is shown by a median relative decrease in RVEF of 10.9% from baseline 279 
on POD2, with four patients experiencing a relative decrease of RVEF in excess of 20.0%. 280 
The observed changes in RV function occur despite preservation of LV function, meaning 281 
changes following lung resection primarily affect the right ventricular-pulmonary vascular 282 
unit. The association between pulmonary function and deterioration in RVEF by POD2 283 
suggests those patients with poorer lung function are also likely to be those with a larger 284 
deterioration in RV function, meaning this group may be at particular risk. 285 
CMR was feasible and well tolerated post-operatively with more than 80% of patients 286 
completing the examination protocol. RVEF assessment was reproducible with coefficients 287 
of variation (CV) between 12.9% and 16.8%. This is the first study to describe CMR in a 288 
lung resection cohort - CVs in this population have not been described. Work in normal 289 
subjects and those with cardiac pathology have shown CVs for RVEF between 8.0 and 290 
10.7%.27 Our study had higher CV's, however post-hoc analyses suggest surgical side was 291 
important to observed variability. Pre-operative CV's were similar for those having left or 292 
right sided resections (12.75% and 13.21% respectively). Post-operatively those patients with 293 
right sided resections had larger CVs (20.48% on POD2 and 16.92% at 2-months) than those 294 
having left sided surgery (11.53% and 13.81% respectively). Future studies using CMR in 295 
this population for mechanistic research, may wish to prioritise patients undergoing left sided 296 
resections. 297 
As described in the introduction, a more complete assessment of RV and pulmonary vascular 298 
function can be provided by measuring the matching between contractility and afterload. The 299 
15 
 
CMR surrogate approximation used in this study has compared favourably to a combined 300 
pulmonary artery catheter and CMR determined coupling measurement in a pulmonary 301 
hypertension cohort.24 This ratio however incorporates a number of assumptions; firstly that 302 
ventricular volume at time zero is negligible, and secondly it calculates end systolic elastance 303 
and not maximal elastance.28-30 Our patients show a SV/ESV ratio of 1.0 which falls 304 
following surgery suggesting a deterioration in the matching of contractility and afterload 305 
which is still present 2-months following surgery.  306 
Although widely hypothesized, increased afterload following lung resection has not been 307 
demonstrated.10, 18, 21 PAAT and PA distensibility are indices of afterload that do not assume 308 
constant flow (as PVR assumes), providing some insight into the pulsatile nature of afterload.  309 
Reduced PAAT has been associated with abnormal wave reflections (increased pulsatile 310 
afterload) in pulmonary hypertension.26 Reduced PA distensibility suggests decreased 311 
compliance of the pulmonary vessels, increasing afterload.31, 32  312 
We observed a decrease in PAAT in all vessels on POD2, with the greatest decrease in the 313 
operative vessel. At 2-months, main PAAT remains reduced and although non-operative 314 
PAAT returns to pre-operative levels, operative PAAT remains lower. These findings suggest 315 
that post-operatively there is increased afterload in the operative vessel, potentially due to 316 
increased wave reflection.  317 
There were no changes in main PA distensibility, however determination of distensibility in 318 
this vessel can be complicated by cardiac movement distorting the cross-sectional plane, 319 
compromising the measurement.33 This was our experience, with diastolic increases in cross-320 
sectional area not reflected in either changes in flow in the main PA, or area of the branch 321 
pulmonary vessels. Operative distensibility was lower than pre-operative at 2-months, again 322 
suggesting increased afterload on this side. 323 
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The changes in PAAT and distensibility, in addition to reduced operative PA blood flow, 324 
suggest changes in afterload mainly result from the operative PA. PAAT and distensibility 325 
are surrogate indices of pulsatile afterload but only partially reflect changes in overall 326 
pulmonary artery impedance; this may account for the lack of observed association between 327 
either of these measures and RVEF. In-depth analysis of pulsatile afterload is required to 328 
further explore any association between changes in afterload and RV function following lung 329 
resection. Additionally, it must be recognised that the observed changes in RVEF  could also 330 
occur as a result  of intrinsic changes in RV contractility which could  not be fully accounted 331 
for in this study.  332 
BNP and hsTnT are quantitative biomarkers of myocardial injury. BNP is released in 333 
response to myocardial stretch and has been measured in patients undergoing lung resection, 334 
with elevated peri-operative levels associated with early post-operative cardiopulmonary 335 
complications.34 We observed association between POD2 BNP and both RVEFPOD2 and 336 
ΔRVEFPOD2-pre. We found no association between LVEF and BNP (not shown) suggesting 337 
BNP is released in response to changes within the RV. We found no association with change 338 
in RV function and troponin at any time point. 339 
Clinical Implications 340 
This is the first study showing that RV function is impaired not just in the immediate peri-341 
operative period following lung resection, but months later, long into the recovery period. In 342 
other clinical settings such as heart failure and pulmonary hypertension, RV dysfunction is 343 
associated with poor prognosis and reduced exercise capacity; we hypothesize that reduced 344 
RVEF following lung resection is likely to have clinical sequelae such as dyspnea and 345 
reduced functional capacity. The right ventricle and pulmonary vasculature may provide a 346 
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target for future peri-operative interventions, allowing amelioration of long-term 347 
cardiorespiratory morbidity.  348 
Limitations 349 
Although there is association between duration of critical care admission and post-operative 350 
RV function this does not suggest it is causative. The reasons for remaining in critical care 351 
are multi-factorial and some of the complications that may prolong stay, could in themselves 352 
cause RV dysfunction. This is a proof of concept study and its size means any clinical 353 
associations can only be hypothesis generating and do not allow robust clinical correlation; 354 
future work should fully assess the clinical implications of RV dysfunction.  355 
We made no assessment of RV function during exercise, previous work in this patient group 356 
has consistently shown marked changes in pulmonary haemodynamics and RV function on 357 
exercise.18, 35 While the deterioration in RVEF observed is modest, we suggest the changes 358 
observed at rest would be exacerbated during exercise. 359 
CMR is a reference method for assessing RV volumes but its use in this group is limited, 360 
firstly by availability and secondly by suitability in the immediate post-operative patient. 361 
Although withdrawals were well within the number allowed by the study’s power analysis, a 362 
group of participants were unable to undergo CMR assessment post-operatively. A validated 363 
bedside alternative to CMR for the assessment of RV structure and function, potentially 364 
utilising transthoracic echocardiography, biomarkers or a combination would have utility in 365 
this population. 366 
CONCLUSIONS 367 
Right ventricular function is impaired immediately post-operatively following lung resection 368 
and this persists at 2-months. There is a deterioration in the SV/ESV ratio with evidence of 369 
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increased afterload. There was moderate association between post-operative RV function and 370 
B-type natriuretic peptide. Future work should focus on assessing the mechanisms and 371 
clinical implications of post-operative RV dysfunction and on assessment of RV function 372 
during exercise.   373 
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 491 
FIGURE LEGENDS 492 
Figure 1 (A-C). Ventricular ejection fraction and coupling over time  493 
For box plots, the middle horizontal line represents the median, the boxes represent the 494 
interquartile range (IQR) and the whiskers represent the range of values no greater than 1.5 495 
times the IQR. Circles represent outliers and are values 1.5-3 times IQR.  496 
(A) Decrease in right ventricular ejection fraction (RVEF) on post-operative day (POD) 2, 497 
remaining reduced at 2-months. (B) No changes in left ventricular ejection fraction (LVEF) 498 
over time. (C) Deterioration in the stroke volume/end systolic volume ratio (SV/ESV) over 499 
study period.  500 
Figure 2 (A-B). Pulmonary artery flow over time  501 
For box plots, the middle horizontal line represents the median, the boxes represent the IQR 502 
and the whiskers represent the range of values no greater than 1.5 times the IQR. Circles 503 
represent outliers and are values 1.5-3 times IQR. Blue bars represent the Main pulmonary 504 
artery (MPA), green bars represent the operative pulmonary artery (OPA) and white bars 505 
represent the non-operative pulmonary artery (NPA)  506 
 (A) Flow in the MPA increases on POD2 before returning to pre-op levels by 2-months. (B) 507 
Post-operative distribution of CO between the two pulmonary arteries is altered, with reduced 508 
flow through the OPA on POD2 and at 2-months. 509 
Figure 3 (A-C). Pulmonary artery acceleration time (PAAT) and distensibility over time  510 
For box plots, the middle horizontal line represents the median, the boxes represent the IQR 511 
and the whiskers represent the range of values no greater than 1.5 times the IQR. Circles and 512 
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positive symbols (+) represent outliers and are values 1.5-3 and >3 times IQR respectively. 513 
Blue bars represent the Main pulmonary artery (MPA), green bars represent the operative 514 
pulmonary artery (OPA) and white bars represent the Non-operative pulmonary artery 515 
(NPA).  516 
(A) PAAT in the MPA is reduced post-operatively, remaining reduced from pre-op levels at 517 
2-months. (B) PAAT in the OPA is reduced on POD2 and despite partial recovery, remains 518 
reduced at 2-months. PAAT in the NPA is reduced on POD2 but recovers by 2-months. 519 
PAAT is lower in the OPA on POD2 and at 2-months. (C) Distensibility in the OPA is 520 
reduced on POD2 and at 2-months. Distensibility in the OPA is lower than the NPA at 2-521 
months.   522 
Figure 4 (A-D). Biomarkers of myocardial function  523 
For box plots, the middle horizontal line represents the median, the boxes represent the IQR 524 
and the whiskers represent the range of values no greater than 1.5 times the IQR. Circles and 525 
positive symbols (+) represent outliers and are values 1.5-3 and >3 times IQR respectively.   526 
(A) Changes in B-type natriuretic peptide (BNP) over time, peaking on post-operative day 527 
(POD) 2. (B) Changes in High sensitivity troponin T (hsTnT) over time, peaking on POD1. 528 
(C) Moderate association of change in right ventricular ejection fraction from pre-op to 529 
POD2 (ΔRVEF [POD2-Pre]) and BNP on POD2 (D) No association with ΔRVEF [POD2-530 
Pre] and hsTnT on POD2.  531 
 532 
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Table 1. Patient characteristics 
Patient characteristics n = 27 
Age, yr 67.0 (59.0, 74.0) 
Sex, n Female 17 (63.0%) 
Smoking  
 None, n (%) 2 (7.4%) 
 Former, n (%) 12 (44.4%) 
 Active, n (%) 13 (48.1%) 
Pre-operative pulmonary function  
 SaO2 on air, % 96.4 (1.7) 
 FEV1, L 1.9 (1.6, 2.4) 
 % Predicted FEV1, % 87.5 (25.1) 
 FEV1/FVC ratio, % 64.1 (14.8) 
 TLCO, mmol/kPa/min 5.2 (1.7) 
 % Predicted TLCO, % 66.6 (15.2) 
Operative Variables  
 Pneumonectomy, n (%) 1 (3.7%) 
 Lobectomy, n (%) 22 (81.5%) 
 Bilobectomy, n (%) 4 (14.8%) 
 Right sided procedure, n (%) 17 (63.0%) 
 Segments resected, n 5 (3, 5) 
 Duration of surgery, mins 146.0 (116.0, 169.0) 
 Duration of OLV, mins 56.0 (48.0, 84.0) 
 Intra-op fluid administration, mls 933.3 (402.9) 
Pathology 
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 Primary lung cancer 24 (88.9%) 
 Metastatic malignancy 1 (3.7%) 
 Benign 2 (7.4%) 
Comorbidities*  
 History of Cancer, n (%) 7 (25.9%) 
 COPD, n (%) 6 (22.2%) 
 Hypertension, n (%) 9 (33.3%) 
 Ischemic Heart Disease, n (%) 6 (22.2%) 
 Diabetes Mellitus, n (%) 0 
 Peripheral Vascular Disease, n (%) 5 (18.5%) 
 Obesity, n (%) 2 (7.4%) 
 Alcoholism, n (%) 0 
Thoracoscore (%) 0.7 (0.5, 0.8) 
Critical Care Unit Length of Stay (Days) 2.0 (1.2, 2.2) 
Hospital Length of Stay (Days) 8 (7, 11) 
*As per Thoracoscore definition of comorbidities. 
Data are presented as mean (SD) or median (Q1, Q3). 
SaO2, oxygen saturation; FEV1, forced expiratory volume in 1 second; FVC, forced 
vital capacity; TLCO,  transfer factor for carbon monoxide; OLV, one lung 
ventilation; COPD, chronic obstructive pulmonary disease. 
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Table2. Ventricular Volumes and Function over Time 
 Pre-op POD2  2 months p-value 
 n = 26 n = 22 n = 24  
HR (bpm) 64.4 (13.0) 77.0 (11.0)‡ 69.4 (10.3)§  0.002* 
 
    
Right ventricle volume measurements   
 RVEF (%) 50.5 (6.9) 45.6 (4.5)‡ 44.9 (7.7)‡ 0.003* 
 RVEDV (ml) 119.1 (25.4) 125.9 (22.5) 109.4 (31.6) 0.019* 
 RVESV (ml) 59.8 (17.1) 68.6 (14.5)‡ 59.8 (17.6) 0.040* 
 RVSV (ml) 59.3 (12.0) 57.3 (10.7) 49.6 (16.5)‡ 0.002* 
 RVSV/RVESV 1.0 (0.9, 1.2) 0.8 (0.7, 1.0)§ 0.8 (0.8, 1.0)§ 0.011† 
 
 
   
Left ventricle volume measurements   
 LVEF (%) 58.4 (7.1) 57.4 (7.3) 59.7 (9.3) 0.621* 
 LVEDV (ml) 109.2 (19.5) 106.3 (19.2) 93.6 (28.2)‡ 0.001* 
 LVESV (ml) 46.0 (13.2) 46.0 (14.2) 37.7 (13.1) 0.019* 
 LVSV (ml) 63.2 (11.7) 60.3 (9.0) 55.9 (18.0)‡ 0.004* 
Data are presented as mean (SD) or median (Q1, Q3). 
*One-way repeated measures ANOVA. 
†Friedman's test.  
‡ Significant difference from Pre-op (paired t-test, p<0.05). 
§ Significant difference from Pre-op (Wilcoxon signed rank test, p<0.05). 
§ Significant difference from POD2 (paired t-test, p<0.05). 
POD, post-operative day; HR, heart rate; bpm, beats per minute; RVEF, right 
ventricular ejection fraction; RVEDV, right ventricular end diastolic volume; RVESV, 
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right ventricular end systolic volume; RVSV, right ventricular stroke volume; LVEF, 
left ventricular ejection fraction; LVEDV, left ventricular end diastolic volume; 
LVESV, left ventricular end systolic volume; LVSV, left ventricular stroke volume. 
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Table3. PAAT and Distensibility Index  
 Pre-op  POD2  2-months p-value 
 n = 26 n = 22 n = 24  
Pulmonary artery flow (L/min)   
 Main PA flow 6.6 (1.7) 8.0 (1.6) ‡ 6.5 (1.7) § 0.004* 
 Operative PA flow  3.0 (0.8) 2.3 (0.7) ‡ 2.3 (0.8) ‡ 0.004* 
 Non-operative PA flow  2.8 (1.0) 4.7 (1.4) ‡ ll 3.8 (1.5) ‡ § ll <0.001* 
     
Pulmonary Artery Acceleration Time (PAAT, ms)   
 Main PA  115.9 (20.7) 82.7 (18.9) ‡ 104.0 (19.5) § <0.001* 
 Operative PA  124.7 (19.3) 82.1 (23.0) ‡ 106.0 (23.9) ‡§  <0.001* 
 Non-operative PA  128.0 (24.8) 100.5 (18.8) ‡ll 121.4 (20.4) §ll <0.001* 
     
Distensibility (%)   
 Main PA 32.0 (26.9, 46.0) 29.8 (22.3, 38.8) 28.4 (25.8,  39.6) 0.818† 
 Operative PA 65.2 (25.5) 50.7 (16.9)  51.8 (16.2)  0.027* 
 Non-operative PA 62.6 (23.2) 54.4 (17.7) 69.2 (28.0) §ll 0.120* 
Data are presented as mean (SD) or median (Q1, Q3). 
*One-way repeated measures ANOVA. 
† Friedman’s test. 
‡ Significant difference from pre-op (paired t-test, p<0.05). 
§ Significant difference from POD2 (paired t-test, p<0.05). 
ll Significant difference from operative vessel at given timepoint (independent samples t-test, 
p<0.05). 
POD, post-operative day; PA, pulmonary artery. 
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Table 4. Biomarkers of myocardial function 
 
Immediate 
Pre-op 
Immediate 
Post-op 
POD1 POD2 2-months p-value 
 n = 27 n = 27 n = 27 n = 27 n = 24  
BNP (pg/ml) 
28.0 (5.0, 
160.0) 
32.0 (6.0, 
170) 
71.0 (5.0, 
381.0)† 
93.0 (5.0, 
304.0)† 
28.5 (5.0, 
199.0) § ll 
<0.001* 
       
 n = 26 n = 26 n = 26 n = 26 n = 22  
hsTnT (pg/ml) 
6.8 (3.0, 
27.2) 
6.9 (3.0, 
23.2) 
12.3 (3.7, 
21.9)†‡ 
9.5 (3, 
20.7)‡ 
9.0 (3.9, 
24.9)‡ 
<0.001* 
Data are presented as median (Q1, Q3). 
*Friedman's test. 
† Significant difference from Pre-op (Wilcoxon signed rank test,  p<0.05). 
‡ Significant difference from Immediate Post-op (Wilcoxon signed rank test, p<0.05). 
§ Significant difference from POD1 (Wilcoxon signed rank test, p<0.05). 
ll Significant difference from POD2 (Wilcoxon signed rank test, p<0.05). 
POD, post-operative day; BNP, B-type natriuretic peptide; hsTnT, high sensitivity troponin T. 
 
